Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Page 1
Optimizing CFTR modulator therapy management for cystic fibrosis through the ReX platform.
Yaacoby-Bianu K, Cohen-Cymberknoh M, Shoseyov D, Lavi T, Ostrovski A, Shteinberg M, Livnat G. Yaacoby-Bianu K, et al. Among authors: shteinberg m. Front Pediatr. 2023 Dec 19;11:1300968. doi: 10.3389/fped.2023.1300968. eCollection 2023. Front Pediatr. 2023. PMID: 38178914 Free PMC article.
Consequently, this device may potentially reduce costs to healthcare providers. Further larger and long-term studies are required to examine the clinical benefits of the ReX platform....
Consequently, this device may potentially reduce costs to healthcare providers. Further larger and long-term studies are required to …
CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis.
Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG. Taylor-Cousar JL, et al. Among authors: shteinberg m. Lancet. 2023 Sep 30;402(10408):1171-1184. doi: 10.1016/S0140-6736(23)01609-4. Epub 2023 Sep 9. Lancet. 2023. PMID: 37699418 Review.
Following discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989 and subsequent elucidation of the varied CFTR protein abnormalities that result, a new era of cystic fibrosis management has emerged-one in which scientific principles translated fr …
Following discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989 and subsequent elucidation of the varied …
Prevalence, trends and outcomes of long-term inhaled antibiotic treatment in people with cystic fibrosis without chronic Pseudomonas aeruginosa infection - A European cystic fibrosis patient registry data analysis.
Orenti A, Mei-Zahav M, Boracchi P, Lindblad A, Shteinberg M; ECFSPR Scientific Committee. Orenti A, et al. Among authors: shteinberg m. J Cyst Fibros. 2023 Jan;22(1):103-111. doi: 10.1016/j.jcf.2022.08.010. Epub 2022 Aug 28. J Cyst Fibros. 2023. PMID: 36045028
BACKGROUND: Long-term treatment with inhaled antibiotics is recommended for people with cystic fibrosis (pwCF) chronically infected with Pseudomonas aeruginosa (PA). ...CONCLUSIONS: Many pwCF without chronic PA infection are receiving long-term treatment with inhale …
BACKGROUND: Long-term treatment with inhaled antibiotics is recommended for people with cystic fibrosis (pwCF) chronically infected w …
4-week daily airway clearance using oscillating positive-end expiratory pressure versus autogenic drainage in bronchiectasis patients: a randomised controlled trial.
Livnat G, Yaari N, Stein N, Bentur L, Hanna M, Harel M, Adir Y, Shteinberg M. Livnat G, et al. Among authors: shteinberg m. ERJ Open Res. 2021 Nov 8;7(4):00426-2021. doi: 10.1183/23120541.00426-2021. eCollection 2021 Oct. ERJ Open Res. 2021. PMID: 34760994 Free PMC article.
Lung clearance index (LCI) is a measurement of ventilation inhomogeneity. Its responsiveness to long-term airway clearance is unknown. We aimed to compare two methods of daily airway clearance over 4 weeks: autogenic drainage (AD) and oscillating positive airway pressure ( …
Lung clearance index (LCI) is a measurement of ventilation inhomogeneity. Its responsiveness to long-term airway clearance is unknown …
Bronchiectasis Exacerbations: Definitions, Causes, and Acute Management.
Perl S, Shteinberg M. Perl S, et al. Among authors: shteinberg m. Semin Respir Crit Care Med. 2021 Aug;42(4):595-605. doi: 10.1055/s-0041-1730944. Epub 2021 Jul 14. Semin Respir Crit Care Med. 2021. PMID: 34261183
Despite these gaps in our knowledge of the biology of PEx, antimicrobial therapy directed against the identified pathogens in sputum is currently the recommended therapeutic strategy. Various long-term therapies, including antimicrobial and anti-inflammatory strategies, ha …
Despite these gaps in our knowledge of the biology of PEx, antimicrobial therapy directed against the identified pathogens in sputum is curr …
The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis.
Araújo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Stone G, Trautmann M, Davis A, Dimakou K, Polverino E, De Soyza A, McDonnell MJ, Chalmers JD. Araújo D, et al. Among authors: shteinberg m. Eur Respir J. 2018 Jan 31;51(2):1701953. doi: 10.1183/13993003.01953-2017. Print 2018 Feb. Eur Respir J. 2018. PMID: 29386336 Free article.
Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis.
Chalmers JD, Aliberti S, Filonenko A, Shteinberg M, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Gerlinger C, Sotgiu G, Operschall E, Rutherford RM, Dimakou K, Polverino E, De Soyza A, McDonnell MJ. Chalmers JD, et al. Among authors: shteinberg m. Am J Respir Crit Care Med. 2018 Jun 1;197(11):1410-1420. doi: 10.1164/rccm.201711-2202OC. Am J Respir Crit Care Med. 2018. PMID: 29357265
OBJECTIVES: To establish if there is a "frequent exacerbator phenotype" in bronchiectasis and the impact of exacerbations on long-term clinical outcomes. METHODS: We studied patients with bronchiectasis enrolled from 10 clinical centers in Europe and Israel, with up to 5 y …
OBJECTIVES: To establish if there is a "frequent exacerbator phenotype" in bronchiectasis and the impact of exacerbations on long-term …
[LONG TERM TREATMENT WITH MACROLIDES IN CHRONIC LUNG DISEASES].
Shteinberg M, Schneer S, Lavon O, Adir Y. Shteinberg M, et al. Harefuah. 2016 Sep;155(9):567-571. Harefuah. 2016. PMID: 28530085 Review. Hebrew.
In cystic fibrosis patients colonized with pseudomonas aeruginosa, long term treatment with azithromycin reduces exacerbations and presents improved lung function. A similar effect on prevention of exacerbations has been demonstrated in noncystic fibrosis bronchiectasis. I …
In cystic fibrosis patients colonized with pseudomonas aeruginosa, long term treatment with azithromycin reduces exacerbations and pr …
Use of inhaled tobramycin in cystic fibrosis.
Shteinberg M, Elborn JS. Shteinberg M, et al. Adv Ther. 2015 Jan;32(1):1-9. doi: 10.1007/s12325-015-0179-3. Epub 2015 Jan 27. Adv Ther. 2015. PMID: 25620537 Review.
It leads to a reduced quality of life, acceleration of the decline in lung function, and increased frequency and severity of pulmonary exacerbations. Tobramycin, administered by inhalation as a long-term therapy, decreases bacterial density in airways, reduces exacerbation …
It leads to a reduced quality of life, acceleration of the decline in lung function, and increased frequency and severity of pulmonary exace …
15 results